BRAIN Journal-Electrophysiological Neuroimaging using sLORETA Comparing 100 Schizophrenia Patients to 48 Patients with Major Depression -Figure 1. Group comparisons designed for isolating the mesolimbic Dopamine D2

<p>All patients diagnosed with Schizophrenia were medicated with atypical antipsychotics, Olanzapine (dose 5mg/day to 20mg/day) or Risperidone (dose 1mg/day to 4mg/day) blocking both Dopamine D2 and Serotonin 5-HT2 receptors. Whereas, all of the patients diagnosed with Major Depression or Depressive Episode were medicated with Sertraline (50mg/day to 200mg/day maximum dose) or Citalopram (20mg/day to 40mg/day maximum dose). This research protocol was approved by the Bioethical Commission of the Medical University of Lublin.